BLCM:NSD-Bellicum Pharmaceuticals, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 3.06

Change

-0.01 (-0.33)%

Market Cap

USD 0.02B

Volume

0.56M

Average Target Price

USD 4.50 (+47.06%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens. It has collaboration and license agreements with Adaptimmune Therapeutics plc, Agensys, Inc., BioVec Pharma, Inc., ARIAD Pharmaceuticals, Inc., and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Houston, Texas.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-12-03 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

+0.17 (+0.07%)

USD58.95B 22.22 17.39
MRNA Moderna, Inc

+14.26 (+9.97%)

USD56.59B N/A N/A
REGN Regeneron Pharmaceuticals, Inc

-6.29 (-1.25%)

USD53.90B 18.51 14.53
SGEN Seagen Inc

+3.12 (+1.76%)

USD31.69B 66.86 62.62
BNTX BioNTech SE

-2.41 (-1.99%)

USD29.16B -99,999.99 N/A
ALXN Alexion Pharmaceuticals, Inc

-1.69 (-1.38%)

USD26.86B 28.49 26.92
RPRX Royalty Pharma plc

+0.51 (+1.22%)

USD26.12B 22.60 9.98
GMAB Genmab A/S

+0.03 (+0.08%)

USD24.77B 26.59 2.61
BGNE BeiGene, Ltd

-5.69 (-2.51%)

USD21.71B N/A N/A
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing BLCM

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 137.21% 88% B+ 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 137.21% 88% B+ 91% A-
Trailing 12 Months  
Capital Gain 277.78% 92% A- 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 277.78% 92% A- 95% A
Trailing 5 Years  
Capital Gain -85.90% 22% F 6% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -85.90% 22% F 6% F
Average Annual (5 Year Horizon)  
Capital Gain 8.39% N/A N/A 62% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.39% N/A N/A 58% F
Risk Return Profile  
Volatility (Standard Deviation) 128.67% N/A N/A 7% F
Risk Adjusted Return 6.52% N/A N/A 36% F
Market Capitalization 0.02B 5% F 7% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 40.34 3% F 2% F
Price / Cash Flow Ratio -0.24 11% F 59% F
EV/EBITDA 0.10 78% C+ 96% A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital -152.19% 13% F 5% F
Return on Assets -34.90% 35% F 10% F
Debt to Equity Ratio -98.09% 93% A 95% A
Technical Ratios  
Short Ratio 2.79 63% D 54% F
Short Percent 7.20% 45% F 29% F
Beta 2.21 19% F 10% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.